UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other jurisdi ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2021 Earnings Conference Call November 3, 2021 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Doug Ingram - President & Chief Executive Officer Ian Estepan - Executive Vice President & Chief Financial Officer Dallan Murray - Senior Vice President & Chief Commercial Officer Gilmore O'Neill - Executive Vice President of R&D & Chief Medical Officer Louise Rodino-Klapac - Executive Vice President & Chief Scientific Officer Conferen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other ...

Summary of Sarepta Therapeutics, Inc. Conference Call Company Overview - **Company**: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - **Industry**: Biotechnology, specifically focusing on therapies for Duchenne muscular dystrophy (DMD) Key Highlights 1. **Progress on SRP-5051**: The company is ahead of schedule in its clinical trials, aiming to dose the first patient in Q4 2021, earlier than initially planned [2][3] 2. **MOMENTUM Trial**: The pivotal trial for accelerated approval is referred to as Part B of the MOMENTUM study, with promising initial data showing significant exon skipping and dystrophin production compared to existing therapies [4][5] 3. **Dystrophin Production**: Initial results indicated an exon skipping rate 18 times greater than eteplirsen, with a projected dystrophin level exceeding 10% after one year of treatment [4][5][16] 4. **FDA Interaction**: The company has established a positive relationship with the FDA's Neurology division, which has experience with DMD, and has received guidance on using dystrophin as a surrogate endpoint for accelerated approval [7][9] 5. **Safety Profile**: Concerns regarding hypomagnesemia have been addressed, with the company confident that it can be managed through oral supplements [18][20] 6. **PPMO Platform**: The PPMO technology has the potential to treat approximately 80% of DMD patients, with ongoing efforts to develop therapies for rare mutations [26][39] 7. **Gene Therapy Synergy**: The company is exploring the potential for synergistic effects between its PPMO platform and gene therapy, SRP-9001, to provide comprehensive treatment options for DMD [28][29] 8. **Competitive Advantage**: Sarepta claims to have unique results in human trials with its PMO and PPMO therapies, setting it apart from competitors [32][34] Additional Insights 1. **Patient Compliance**: The company reports a compliance rate of over 90% for its therapies, indicating strong patient adherence despite the challenges posed by the pandemic [13] 2. **Future Directions**: The company plans to expand its research into other neuromuscular diseases and is focused on developing additional constructs for other skip amenable mutations [39][38] 3. **Upcoming Trials**: The company is preparing for the launch of the 301 study, which will be a double-blind, placebo-controlled trial with a primary endpoint of functional output [48][50] This summary encapsulates the key points discussed during the conference call, highlighting the company's advancements, regulatory interactions, and future plans in the biotechnology sector focused on DMD.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Morgan Stanley 19th Annual Global Healthcare Conference Call September 13, 2021 1:15 PM ET Company Participants Doug Ingram - Chief Executive Officer Ian Estepan - Chief Financial Officer Conference Call Participants Matthew Harrison - Morgan Stanley Matthew Harrison Well, good afternoon everybody. Thanks for joining us for our next session. I am Matthew Harrison, one of the biopharma analysts here at Morgan Stanley. Very pleased to have Sarepta with us for the next ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q2 2018 Results Conference Call August 4, 2021 4:30 PM ET Company Participants Mary Jenkins - Senior Manager, IR Doug Ingram - President and CEO Ian Estepan - EVP and CFO Dallan Murray - SVP and Chief Commercial Officer Dr. Gilmore O’Neill - EVP, R&D and Chief Medical Officer Dr. Louise Rodino-Klapac - EVP and Chief Scientific Officer Conference Call Participants Gena Wang - Barclays Tazeen Ahmad - BoA Brian Abrahams - RBC Capital Markets Alethia Young - Cantor Anupa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other jurisdiction of incorporation or organization) 215 First Street, Suite 415 Cambridge, MA 02142 (Address of principal executive offices) (Zip Cod ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bank of America Securities 2021 Napa BioPharma Virtual Conference June 16, 2021 10:30 AM ET Company Participants Doug Ingram - President and CEO Ian Estepan Stan - CFO Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Tazeen Ahmad Okay. Good morning, everybody. Thanks for joining us at the Bank of America Virtual Napa Conference. It's my pleasure this morning to have with us Sarepta as our next presenting company. For the next 50 minutes, I ha ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Goldman Sachs 42nd Annual Global Healthcare Conference Call June 10, 2021 1:20 PM ET Company Participants Douglas Ingram - President and Chief Executive Officer Ian Estepan - Executive Vice President and Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc. Salveen Richter Good afternoon, everyone. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. Thanks for joining us. We are really pleased to have Sarepta with u ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) RBC Capital Markets Global Healthcare Conference May 18, 2021 2:30 PM ET Company Participants Ian Estepan - EVP & CFO Douglas Ingram - President, CEO & Director Conference Call Participants Brian Abrahams - RBC Capital Markets Q - Brian Abrahams Hi, good afternoon everyone. I'm Brian Abrahams, Senior Biotech Analyst at RBC Capital Markets. I'm really pleased to have with us our next presenting company, Sarepta Therapeutics, represented by their CFO, Ian Estepan. Ian, ...